Confirm a stable target identifier before relying on this context across project surfaces.
CHEMBL372 Target Snapshot
Homo sapiens · ORGANISM · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Confirm a stable target identifier before relying on this context across project surfaces.
Homo sapiens
Review this target as Homo sapiens.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Homo sapiens as ChEMBL target CHEMBL372. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Homo sapiens still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need the strongest disease program and evidence level in one place.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Homo sapiens |
| Target Type | ORGANISM |
| Organism | Homo sapiens |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
How to read this target
Review this target as Homo sapiens.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL176441 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL1203039 | 10.92 | IC50 | 0.012 | Preclinical |
| CHEMBL1203038 | 10.92 | IC50 | 0.012 | Preclinical |
| CHEMBL351742 | 10.86 | IC50 | 0.0138 | Preclinical |
| CHEMBL1203053 | 10.8 | IC50 | 0.016 | Preclinical |
| CHEMBL1203033 | 10.77 | IC50 | 0.017 | Preclinical |
| CHEMBL1203019 | 10.74 | IC50 | 0.018 | Preclinical |
| CHEMBL108730 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL433611 | 10.7 | IC50 | 0.02 | Preclinical |
| CHEMBL295945 | 10.7 | IC50 | 0.02 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
ADME — 7,693 assays, 3 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 7,627 | 3 | 4.7 |
| assay format | 64 | 0 | — |
| cell-free format | 2 | 0 | — |
Functional — 3,764 assays, 4,555 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 3,708 | 4,554 | 6.2 |
| assay format | 50 | 1 | 8.2 |
| tissue-based format | 6 | 0 | — |
Toxicity — 1,308 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 1,280 | 0 | — |
| assay format | 28 | 0 | — |